Latest Articles
Discover insights and stories from our community of writers
Filter by Category:
All Categories
AI & Frontier Technology
Arts, Entertainment & Culture
Business & Corporate
Business Startups
Events
Local & Regional
Marketing & Advertising & PR
Media
Non-Profit
Technology
Showing posts from: Business & Corporate
Most Active Authors (Last 30 Days):
OS Therapies Inc. is on the brink of revolutionizing osteosarcoma treatment with its leading therapy, OST-HER2, achieving significant clinical and regulatory milestones. With the FDA's nod and a robust pipeline poised for commercial launch, OS Therapies is setting a new standard in a field that hasn't seen innovation in over four decades.
- Investing in OS Therapies Inc. offers a competitive edge with its pioneering osteosarcoma treatment and potential for dramatic stock re-ratings.
- Stonegate Capital Partners has begun covering OS Therapies Inc., highlighting its clinical, regulatory, and financial progress, and anticipating a U.S. launch in 2026.
- OS Therapies Inc.'s advancement in osteosarcoma treatment represents a significant leap forward in cancer therapy, offering hope to patients with few options.
- OS Therapies is not just for humans; their subsidiary, OS Animal Health, is bringing their cancer therapy to dogs with positive trial results.
1 min read
Read more